BERWYN, PA — Panavance Therapeutics Inc. has shared promising interim findings from its ongoing Phase 1 clinical trial investigating misetionamide (GP-2250), a novel second-line therapy for advanced pancreatic cancer. These results, presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, demonstrate encouraging safety and efficacy for the combination of misetionamide and gemcitabine.
To date, the dose escalation trial has enrolled 55 patients across seven U.S. clinical sites. The early data show that the combination therapy has been well-tolerated, with no additional toxicities beyond those expected from gemcitabine alone. The study also highlights the synergistic activity of misetionamide, which targets three major transcription factors involved in tumor growth and angiogenesis, including c-MYC, NFκB, and HIF1α.
“The combination of misetionamide and gemcitabine has shown promising synergistic activity, with around 42% of patients experiencing either a partial response or stable disease,” said Dr. Anup Kasi, lead investigator and Associate Professor of Medical Oncology at the University of Kansas Cancer Center. “The extent of tumor regression observed with this combination appears to compare favorably with historical outcomes from gemcitabine alone. These interim results suggest the combination of misetionamide plus gemcitabine may offer a meaningful new treatment option for patients with pancreatic cancer.”
Panavance plans to propel further clinical studies based on misetionamide’s novel mechanism of action and its demonstrated potential across 13 xenograft models.
Greg Bosch, Chairman and CEO of Panavance, emphasized the significance of these findings. “I look forward to discussing these very promising preliminary results with colleagues at BIO. These advances bring us another step closer to providing transformative therapies for patients with pancreatic cancer, which has historically been difficult to treat,” Bosch stated.
The promising trial results were summarized in a poster titled “Interim Open-Label Phase 1 Results of Misetionamide (GP-2250): A Small Molecule Antineoplastic That Inhibits Three Major Transcription Factors,” presented by Dr. Kasi at ASCO on May 31, 2025.
Panavance’s early-stage success signals the potential for misetionamide to address an urgent need in the fight against pancreatic cancer, offering renewed hope for improved patient outcomes in one of the most challenging cancers to treat.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.